13F reference period
Q2 2026
Security Snapshot
Phathom Pharmaceuticals, Inc. - Common Stock (PHAT) Institutional Ownership
CUSIP: 71722W107
13F Institutional Holders and Ownership History from Q4 2019 to Q3 2026
Institutions Reporting
160
Shares (Excl. Options)
72.07M
Full value: 72,073,900 · shares · 30 Jun 2026Price
$10.85
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- PHAT on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 72,073,900
- Total 13F value
- $782,058,148
- Portfolio coverage rank
- 0%
- Share change
- +3,189,902
- Value change
- +$34,337,390
- Number of holders
- 160
- Shares outstanding
- 79,611,764
- SEC-reported price per share
- $7.30
- Insider filing price
- $7.30
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- PHAT - Phathom Pharmaceuticals, Inc. - Common Stock is tracked under CUSIP 71722W107.
- 160 institutions reported positions in Q2 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 173 to 160 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$765.46M
Full value: $765,464,329 · USD · 31 Mar 2026.$782.06M
Full value: $782,058,148 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 160 institutions filings for Q2 2026.
Security key
71722W107
13F reference period
Q2 2026
13F holders
160
13D/G owners
5
CIK / CUSIP context first
Open Q2 2026 holders
PHAT full holder history
Phathom Pharmaceuticals, Inc. SEC filings
Phathom Pharmaceuticals, Inc. company facts
Phathom Pharmaceuticals, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 71722W107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
PHAT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Frazier Life Sciences Public Fund, L.P. | 8.6% | 0% | $70,447,299 | 5,985,327 | 0% | James N. Topper | 01 Nov 2025 | |
| BlackRock, Inc. | 5.5% | +18% | $47,508,320 | +$12,503,117 | 4,378,647 | +36% | BlackRock, Inc. | 30 Jun 2026 |
| Carlyle Group Inc. | 4.9% | $30,142,485 | 3,496,808 | Carlyle Group Inc. | 28 Aug 2025 | |||
| MILLENNIUM MANAGEMENT LLC | 4.2% | -22% | $36,627,799 | -$8,707,960 | 3,375,834 | -19% | Millennium Management LLC | 30 Jun 2026 |
| PRUDENTIAL FINANCIAL INC | 0% | -100% | $8,705 | -$24,547,397 | 2,630 | -100% | PRUDENTIAL FINANCIAL INC | 31 May 2025 |
As of 30 Jun 2026,
160
institutional investors reported holding
shares of
Phathom Pharmaceuticals, Inc. - Common Stock (PHAT).
This represents
91%
of the company’s total
outstanding shares.
72.07M
Full value: 72,073,900 · shares · 30 Jun 202679.61M
Full value: 79,611,764 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
77%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 16% | 12,466,489 | 0% | 2.9% | $135,261,406 |
| Medicxi Ventures Management (Jersey) Ltd | 9.4% | 7,464,572 | 0% | 46% | $80,990,606 |
| BlackRock, Inc. | 5.7% | 4,525,129 | +11% | 0% | $49,097,648 |
| Invesco Ltd. | 5.1% | 4,029,731 | -6.8% | 0% | $43,722,581 |
| Carlyle Group Inc. | 4.4% | 3,496,808 | 0% | 0.38% | $37,940,367 |
| MILLENNIUM MANAGEMENT LLC | 4.2% | 3,375,834 | -16% | 0.02% | $36,627,799 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.3% | 2,656,944 | +2.8% | 0% | $28,827,842 |
| GW&K Investment Management, LLC | 2.7% | 2,166,838 | +52% | 0.18% | $23,510,000 |
| FRANKLIN RESOURCES INC | 2.5% | 1,970,828 | +98% | 0% | $21,383,482 |
| NEA Management Company, LLC | 2.5% | 1,960,169 | 0% | 1.3% | $21,267,834 |
| 683 Capital Management, LLC | 2.3% | 1,850,000 | 0% | 1.8% | $20,072,501 |
| GOLDMAN SACHS GROUP INC | 2.2% | 1,778,032 | +184% | 0% | $19,291,647 |
| STATE STREET CORP | 2% | 1,586,323 | +14% | 0% | $17,211,605 |
| Catalys Pacific, LLC | 1.9% | 1,493,854 | 0% | 7.1% | $16,208,316 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 1.8% | 1,462,738 | +21% | 0.02% | $15,871,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 1,315,687 | -0.93% | 0% | $14,277,589 |
| WASATCH ADVISORS LP | 1.6% | 1,307,247 | -2.5% | 0.09% | $14,183,630 |
| Ensign Peak Advisors, Inc | 1.3% | 1,051,913 | -35% | 0.02% | $11,413,256 |
| Propel Bio Management, LLC | 1.3% | 1,050,358 | +25% | 6% | $11,396,384 |
| Point72 Asset Management, L.P. | 1.3% | 1,022,193 | 0.02% | $11,090,794 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1% | 796,631 | +20% | 0% | $8,643,446 |
| SummitTX Capital, L.P. | 0.99% | 789,550 | -21% | 0.23% | $8,566,618 |
| HSBC HOLDINGS PLC | 0.89% | 709,695 | 0% | $7,701,936 | |
| MARSHALL WACE, LLP | 0.84% | 666,090 | -23% | 0.01% | $7,227,078 |
| EcoR1 Capital, LLC | 0.79% | 625,000 | 0% | 0.34% | $6,781,250 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
28
Headline period
Q2 2026
Rows shown
1-25 of 28
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 3,542,484 | $25,856,249 | +$11,999,270 | $7.30 | 16 |
| 2026 Q2 | 72,073,900 | $782,058,148 | +$34,337,390 | $10.85 | 160 |
| 2026 Q1 | 68,888,502 | $765,464,329 | +$57,584,218 | $11.11 | 173 |
| 2025 Q4 | 61,960,214 | $1,025,500,826 | -$3,898,620 | $16.59 | 173 |
| 2025 Q3 | 62,330,243 | $733,626,032 | +$59,060,064 | $11.77 | 132 |
| 2025 Q2 | 57,415,787 | $550,618,405 | -$26,654,537 | $9.59 | 117 |
| 2025 Q1 | 64,025,009 | $401,391,744 | -$24,944,522 | $6.27 | 136 |
| 2024 Q4 | 66,610,653 | $540,837,976 | -$121,495,122 | $8.12 | 141 |
| 2024 Q3 | 72,636,064 | $1,312,668,227 | +$264,199,549 | $18.08 | 133 |
| 2024 Q2 | 58,109,780 | $598,557,394 | +$27,856,700 | $10.30 | 113 |
| 2024 Q1 | 55,378,949 | $588,085,973 | +$14,631,856 | $10.62 | 112 |
| 2023 Q4 | 54,112,686 | $503,299,407 | +$11,390,968 | $9.13 | 115 |
| 2023 Q3 | 43,760,270 | $452,721,621 | +$5,267,236 | $10.37 | 109 |
| 2023 Q2 | 42,778,866 | $612,591,768 | +$176,400,941 | $14.32 | 103 |
| 2023 Q1 | 30,786,694 | $219,689,484 | +$28,315,357 | $7.14 | 83 |
| 2022 Q4 | 28,212,747 | $316,546,824 | -$21,719,929 | $11.22 | 83 |
| 2022 Q3 | 30,185,827 | $334,342,526 | +$38,042,890 | $11.08 | 87 |
| 2022 Q2 | 27,258,631 | $230,064,222 | +$9,335,400 | $8.44 | 88 |
| 2022 Q1 | 25,654,888 | $349,117,442 | -$176,036,740 | $13.61 | 74 |
| 2021 Q4 | 28,574,214 | $561,954,045 | +$49,942,191 | $19.67 | 82 |
| 2021 Q3 | 25,543,470 | $819,833,454 | +$19,152,056 | $32.10 | 81 |
| 2021 Q2 | 24,918,954 | $843,508,479 | +$13,169,188 | $33.85 | 76 |
| 2021 Q1 | 24,475,818 | $919,193,673 | +$1,760,408 | $37.56 | 82 |
| 2020 Q4 | 24,534,138 | $815,024,391 | +$96,707,884 | $33.22 | 75 |
| 2020 Q3 | 21,632,831 | $793,536,439 | -$7,640,662 | $36.67 | 57 |